Cardiovascular Systems Inc. (CSII) Jumps 5.4% on February 16

Equities Staff |

Cardiovascular Systems Inc. (CSII) was among the biggest gainers on the Russell 2000 for Tuesday February 16 as the stock popped 5.4% to $8.59, representing a gain of $0.44 per share. Some 143,916 shares traded hands on 1,317 trades, compared with an average daily volume of 606,214 shares out of a total float of 32.7 million. The stock opened at $8.20 and traded with an intraday range of $8.71 to $8.18.

After today's gains, Cardiovascular Systems Inc. reached a market cap of $280.87 million. Cardiovascular Systems Inc. has had a trading range between $41.28 and $8.00 over the last year, and it had a 50-day SMA of $12.56 and a 200-day SMA of $20.72.

Cardiovascular Systems Inc is a medical technology company. It is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases.

Cardiovascular Systems Inc. is based out of St. Paul, MN and has some 597 employees. Its CEO is Scott R. Ward / David L. Martin.

For a complete fundamental analysis analysis of Cardiovascular Systems Inc., check out’s Stock Valuation Analysis report for CSII. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…